STOCK TITAN
  1. Home
  2. News
  3. PRFX

PainReform Ltd - PRFX STOCK NEWS

Welcome to our dedicated news page for PainReform (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PainReform.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PainReform's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PainReform's position in the market.

News
PainReform Announces Closing of $4 Million Public Offering
Rhea-AI Summary
PainReform, a clinical-stage specialty pharmaceutical company, announced the closing of a $4 million public offering, issuing 5,000,000 ordinary shares and warrants. The offering price was $0.80 per share with warrants exercisable immediately at the same price, expiring in five years. H.C. Wainwright & Co. acted as the exclusive placement agent. The net proceeds will be used for advancing clinical studies and general corporate purposes. The company also amended existing warrants to reduce the exercise price to $0.80 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
offering
-
News
PainReform Announces Pricing of $4 Million Public Offering
Rhea-AI Summary
PainReform (Nasdaq: PRFX) has announced the pricing of a $4 million public offering, consisting of 5,000,000 ordinary shares and warrants. The offering is priced at $0.80 per share with accompanying warrants to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.43%
Tags
offering
-
News
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
Rhea-AI Summary
PainReform (Nasdaq: PRFX) announces groundbreaking results from studies showing superior in-vitro release rates of PRF-110 for post-surgical pain management. PRF-110 released 34%-77% more drug over 96 hours compared to industry leaders, promising extended pain relief and reduced opiate dependency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.21%
Tags
none
News
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
Rhea-AI Summary
PainReform (Nasdaq: PRFX) achieves 50% enrollment in Phase 3 clinical trial for PRF-110 in bunionectomy. No serious adverse events reported. Top-line data expected by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
clinical trial
-
News
PainReform Provides Year-End Business Update
Rhea-AI Summary
PainReform Ltd. (PRFX) provides a business update, reporting enrollment progress in Phase 3 clinical trial for PRF-110, a post-operative pain relief drug. The company aims to announce top-line data by mid-2024. Financially, research and development expenses increased, while general and administrative expenses decreased. The net loss for 2023 was $9.3 million, with cash and cash equivalents of $8.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.42%
Tags
none
-
News
PainReform to Present at the Microcap Conference in Atlantic City
Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) announced its participation at The Microcap Conference on January 30 - February 1, 2024, where CEO Ilan Hadar will present on Track 2 and Track 5. The company will also hold one-on-one meetings with investors and provided contact information for meeting requests and conference registration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
conferences
News
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief
Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) reported in vitro test results comparing its lead product, PRF-110, with the industry leader as a topical analgesia for postoperative pain relief. PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading, including a greater ability to spread evenly due to its viscosity (PRF-110 1,500 cP vs. industry leader 3,000 cP).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) announces a definitive agreement for the immediate exercise of outstanding warrants to purchase up to 467,896 ordinary shares at a reduced exercise price of $2.85 per share, registered pursuant to an effective registration statement on Form F-1 (File No. 333-274220).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
-
News
PainReform Provides Business Update for the Third Quarter of 2023
Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy. The company provided a business update for the third quarter ended September 30, 2023, highlighting the progress of their lead drug candidate, PRF-110, targeting the post-operative extended pain relief market. The update includes details about the initiation of the second part of the Phase 3 trial in bunionectomy, with the enrollment of the first patients and plans for continued enrollment of up to 400 patients in the double-blind study at multiple clinical sites in the U.S. The update also covers the financial results for the nine months ended September 30, 2023, including research and development expenses, general and administrative expenses, financial income, net, and net loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
none
News
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
Rhea-AI Summary
PainReform plans to commence second part of Phase 3 trial for PRF-110 in Q4 2023, with results expected in mid-2024. Positive safety data from first part of trial suggests potential advantage over opioids. PRF-110 has key surgical benefits and addresses unmet need in postoperative pain market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
clinical trial
Stock PRFX logo
PainReform Ltd

Nasdaq:PRFX

PRFX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PRFX Stock Data

1.90M
1.12M
6.17%
29.93%
0.95%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Tel Aviv

About PRFX

painreform is a specialty pharmaceutical company that develops products for the treatment of pain. focused on reformulations of established pain drugs for the us fda 505(b)(2) regulatory pathway, painreform applies unique technologies to enhance efficacy, reduce adverse effects and increase convenience. our mission is to offer pain therapeutics with clinically meaningful benefits to both physicians and patients.